Dr. Jonasch on the CABOSUN Trial in RCC

Eric Jonasch, MD
Published: Tuesday, Nov 21, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).

The CABOSUN study randomized more than 150 patients between sunitinib (Sutent) and cabozantinib (Cabometyx). These individuals had intermediate- and poor-risk features. The progression-free survival (PFS) for cabozantinib was clearly superior to that of sunitinib, states Jonasch.

According to Jonasch, a number of individuals who were on sunitinib came off very early in the study, which may have skewed the curves somewhat in favor of cabozantinib.
 


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).

The CABOSUN study randomized more than 150 patients between sunitinib (Sutent) and cabozantinib (Cabometyx). These individuals had intermediate- and poor-risk features. The progression-free survival (PFS) for cabozantinib was clearly superior to that of sunitinib, states Jonasch.

According to Jonasch, a number of individuals who were on sunitinib came off very early in the study, which may have skewed the curves somewhat in favor of cabozantinib.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x